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Hsp70a b s t r a c t
Multiple myeloma (MM) cells rely on protein homeostatic mechanisms for survival. These mechanisms
could be therapeutically targeted via modulation of the heat shock response. We studied the roles of
Hsp72 and Hsc70, and show that the two major cytoplasmic Hsp70s play a key role in regulating protein
homeostasis and controlling multiple oncogenic pathways in MM, and their inhibition can lead to mye-
loma cell death. Our study provides further evidence that targeting Hsp70 represents a novel therapeutic
approach which may be effective in the treatment of MM.
 2013 The Authors. Published by Elsevier Ltd. Open access under CC BY-NC-ND license.1. Introduction
Heat shock proteins are involved in a wide range of biochemical
processes including folding of nascent polypeptides, degradation of
misfolded proteins, intracellular trafﬁcking, modulating signalling
pathway activity and regulating immune responses [1–4]. The
multi-functional nature of heat shock proteins and their critical
roles in the regulation of protein homeostasis and cell survival
make them good therapeutic targets in cancer [5,6].
Heat shock proteins are found to be overexpressed in a wide
range of cancers, with Hsp90 and Hsp70 being the most studied
of the family. Accumulating evidence implicate them in cancer cell
survival, apoptosis, invasion, metastasis and escape of immune
surveillance. In recent years, more than ten Hsp90 inhibitors have
entered clinical trials against a range of solid and haematological
malignancies, and promising activity has been observed in many
cancers but not others [7]. In addition, efforts are also being madeto develop Hsp70 inhibiting compounds, although these projects
are still in the drug discovery phase [6,8].
Increasing evidences suggest that the functions of heat shock
proteins are complex in cells, with isoforms of the same heat shock
protein at different subcellular locations playing distinctive roles
[7,9]. New co-chaperones are also being identiﬁed linking the heat
shock proteins to previously unknown functions. All of these fac-
tors can inﬂuence the effectiveness of heat shock protein inhibitors
in speciﬁc cell types. A better understanding of the mechanisms
that heat shock proteins exert their cellular effects will enable
the development of targeted therapeutic strategies with increased
activity and reduced toxicity. One approach to achieving this is via
the development of isoform speciﬁc inhibitors and co-chaperone
inhibitors.
To investigate the clinical utility of such an approach in cancer
we investigated multiple myeloma as a model system. Multiple
myeloma (MM) results from the malignant proliferation of plasma
cells in the bone marrow, which is characterised by the secretion of
monoclonal paraprotein [10]. The mechanisms underlying the pro-
duction and secretion of the paraprotein are a potential therapeutic
target as myeloma cells may be sensitive to the generation of pro-
teotoxic stress mediated via the heat shock protein pathway [11].
Previous studies have shown that MM cells are sensitive to
Hsp90 inhibitors; however, the inhibition of Hsp90 is usually
accompanied by the induction of the pro-survival cytosolic
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effect [12,13]. Hsp70 chaperones act upstream of Hsp90 and
present client proteins for further processing [14], as well as mod-
ulating apoptosis [15–17]. Thus targeting the Hsp70s alone or in
combination with Hsp90 offers an appealing target for the treat-
ment of myeloma as well as other secretory tumours [6]. The roles
of Hsp72 and Hsc70, the two major cytosolic isoforms of Hsp70 in
MM have not been well deﬁned. The aim of this study was to in-
crease our understanding of the roles of cytosolic Hsp70 in MM,
as well as to investigate in vitro a MM-speciﬁc therapy based on
targeting the heat shock response.2. Materials and methods
2.1. Cell lines
All MM cell lines were grown in RPMI1640 containing GlutaMax™(Gibco, Invit-
rogen), supplemented with 10% heat-inactivated fetal calf serum (PAA Laborato-
ries). H293T cells were grown in DMEM (Gibco, Invitrogen) supplemented with
10% heat-inactivated fetal calf serum. Cells were cultured at 37 C in a humidiﬁed
gas chamber with 95% air and 5% carbon dioxide. All cell lines used were myco-
plasma-free as conﬁrmed by PCR. Primary CD138+ myeloma cells and bone marrow
stromal cells were obtained and cultured as previously described [18]. Blood sam-
ples were obtained from patients during routine practice following informed con-
sent, and peripheral blood mononuclear cells (PBMCs) were isolated using Ficoll-
Paque Premium (GE Healthcare).
2.2. Lentiviral transduction of shRNAs
Hsp72 shRNA sequence #1 (GGACGAGTTTGAGCACAAG), a scramble control corre-
sponding to sequence #1 (GGACGAGTTGTAGCACAAG), and shRNA #2(GCCATGAC-
GAAAGACAACAAT) were cloned into the pLVTHM vector as described previously [19].
Hsc70 shRNAs #1 (CCAAGACTTCTTCAATGGAAA) and #2(GCAACTGTTGAAGATGA-
GAAA) cloned into pLKO.1 vectors were obtained from The RNAi Consortium (TRC) via
Open Biosystems. A scramble control corresponding to sequence #1
GAAGACTACCACGACTTATAT was cloned into the pLKO.1 vector according to sup-
plier’s protocol (Addgene).
Virus was produced according to protocols published by TRC (http://www.bro-
adinstitute.org/rnai/public/resources/protocols). Cells transduced with pLVTHM
vectors were sorted for the GFP positive population using a FACSAria (BD Biosci-
ences) and stably transduced cells were grown in normal culture media. For double
transductions, cells were then transduced with pLKO.1 vectors. All experiments
were performed within 10 days after transduction with pLKO.1 vectors.
2.3. Cell proliferation assay
Cell proliferation was measured by the colorimetric WST-1 assay (Roche)
according to the manufacturer’s instructions. The WST-1 tetrazolium compound
is bioreduced into a coloured formazan by NADPH or NADH in metabolically active
cells, therefore the amount of absorbance is directly proportional to the number of
living cells in culture. Cells were plated in 100 ll media at a density of 1  104/well
in 96-well plates. To perform WST-1 assay, 10 ll of WST-1 solution was added to
each well and the plates were incubated in a humidiﬁed incubator in 5% CO2 at
37 C. Two hours after incubation, plates were read on a MRX plate reader (Dyna-
tech Laboratories). For lentiviral knockdown studies, cells were harvested 5 days
after pLKO.1 transduction, plated in 96-well plates and the proliferation followed
every 24 h for four days. For small-molecule inhibition studies, cells were treated
with the Hsp70 inhibitor Ver-155008 (Tocris) and WST-1 assays were performed
at indicated time points. For drug combination study, KMS11 and RPMI8226 cells
were treated with an 11-point concentration range of 17-AAG, Ver-155008 or in
combination for 24 h before cell viability was measured by WST-1 assay. The com-
bination index (CI) methods of Chou and Talalay were used to calculate the effect of
drug combination, with values <1 indicating synergism, 1–1.2 additive and values
>1.2 antagonism.
2.4. Apoptosis assays
For the Annexin V/PI double staining assay, cells were collected and resus-
pended in 1X binding buffer (10 mM Hepes/NaOH pH 7.4, 140 mM NaCl, 2.5 mM
CaCl2). 1  105 cells in 200 ll binding buffer were double stained with 2.5 ll Annex-
in V–APC (BD Biosciences) and 2.5 ll 50 lg/ml PI (BD Biosciences). 10,000 cells
were analysed per sample using a BD LSRII ﬂow cytometer.
For PI cell cycle analysis, cells were resuspended in 1ml PBS, then ﬁxed by add-
ing 2.5 ml ice cold absolute ethanol for 15 min. Fixed cells were pelleted by spin-
ning at 1500 rpm for 5 min, then the pellets were resuspended in 500 ll PI
solution (50 lg/ml propidium iodide (BD), 0.1 mg/ml RNase A (Life Technologies)and 0.05% Triton X-100 (BDH) in PBS) and incubated at 37 C for 40 min. After incu-
bation, cells were pelleted and resuspended in 500 ll PBS, then analysed on a BD
LSRII ﬂow cytometer.
2.5. Western blotting and immunoprecipitation
After transduction or small-molecule inhibitor treatment, cells were harvested
and lysed in RIPA buffer (1% w/v sodium deoxycholate, 1% v/v TritonX-100, 1% v/v
Nonident P-40, 0.1% SDS, 150 mM NaCl, 5 mM EDTA, 50 mM Tris, 30 mM NaF) sup-
plemented with 1X protease inhibitor cocktail (Roche), 200 mM phenylmethylsul-
fonyl ﬂuoride (Fluka), and 1 mM Na3VO4 (Sigma–Aldrich). Proteins were resolved
on 10% SDS–PAGE gels, transferred to PVDF membranes (Millipore), blocked with
5% milk and incubated with primary antibodies for two hours at room temperature.
Primary antibodies to Hsp90 (#SPS-771, Stressgen), Hsp72 (#SPA-810, Stressgen);
Hsc70, GRP78 (#sc-376768, Santa Cruz Biotechnology); CDK4, C-RAF, Caspase 3,
ubiquitin (#2906, #9422, #9662 and #3936, Cell Signaling); LAMP-2, Hsf-1, IgK,
Igk (#ab25631, #ab2923, #ab134083 and #ab124719, Abcam) and anti-b actin
antibody (AC-15, Sigma–Aldrich) were used. Membranes were then incubated with
corresponding secondary antibodies conjugated to horseradish peroxidase (Amer-
sham Biosciences) for 1 h at room temperature. ECL-Plus (Amersham Biosciences)
was used for protein band detection on Kodak XAR ﬁlms.
For immunoprecipitation studies, cells were lysed in RIPA buffer supplemented
with 1X protease inhibitor cocktail, 200 mM phenylmethylsulfonyl ﬂuoride, and
1 mM Na3VO4. Equal amounts of protein were incubated with primary anti-IgK or
anti-Igk antibody for 2 h at room temperature followed by incubation with protein
A/G magnetic beads (Thermo Scientiﬁc) for one hour at room temperature. Protein
samples were eluted in 1X sample buffer (50 mM Tris pH6.8, 100 mM dithiothreitol,
2% SDS, 0.1% bromophenol blue and 10% glycerol) and analysed on SDS–PAGE gels as
described above.
For transduction studies, all protein samples were harvested 5 days after trans-
duction with pLKO.1 vectors.
2.6. Enzyme-linked immunosorbent assay (ELISA)
ELISA analysis on myeloma cells was performed as described previously [20].
Secreted and intracellular light chain was detected using the human kappa or lamb-
da ELISA quantiﬁcation kit (Bethyl Laboratories) according to the manufacturer’s
instructions. Cells were cultured for 24 h before the supernatant from 1  106 cells
was diluted 1:100 and used for the quantiﬁcation of Ig secretion. For intracellular Ig,
whole-cell lysates were prepared as described for western blotting and 500 ng of
total protein was used per assay.
2.7. Reactive oxygen species detection
Global levels of reactive oxygen species was detected using Total ROS detec-
tion kit (Enzo) according to the manufacturer’s instructions. Cells were treated
with 5 lM Ver-155008 for 24 h before analysis on a BD LSRII ﬂow cytometer.
As a negative control, 5 lM ROS inhibitor N-acetyl-L-cysteine was added to the
treated cells 30 min before analysis. Histograms were generated using the free
software Flowing (Version 2.5).
2.8. Statistics
All experiments were performed in triplicate. Statistical analysis was performed
using two-tailed student t-test. P-value < 0.05 was considered statistically
signiﬁcant.
3. Results
3.1. Silencing of Hsc70 increases immunoglobulin retention and
reduces the ubiquitin tagging required for proteasome degradation
One of the main characteristics of MM cells is the synthesis of a
large amounts of immunoglobulin (Ig), creating a protein folding
load [21]. To understand if Hsp70 isoforms have a role in Ig homeo-
stasis, we studied the level of Ig light chains (IgK or Igk) in myelo-
ma cells after knockdown of Hsp72 or Hsc70. The expression levels
of Hsp72 and Hsc70 were silenced using two speciﬁc shRNAs
against each protein and the experiments were controlled using
a scrambled shRNA for each isoform. In western blot analysis of
KMS11 and RPMI8226 human MM cells good knockdown of the
individual isoforms was demonstrated, with the empty vector
and scramble controls having no effect. Hsc70 and Hsp72 expres-
sion levels were reduced by more than 90% ﬁve days following len-
tiviral transduction in both cell lines using two shRNAs, apart from
Hsc70 shRNA #1 in RPMI8226 cells, which achieved 50% knock-
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had no effect on the level of Hsc70 protein; whereas silencing of
Hsc70 resulted in a signiﬁcant compensatory induction of Hsp72
in both cell lines (Fig. 1a i&ii).
Further, we performed ELISA assay on cells knocked down for
Hsp72 or Hsc70, and measured the level of Ig light chain secretion
and retention. The data were normalised to an equal cell number or
protein level respectively. Interestingly, silencing of Hsc70 but not
Hsp72 signiﬁcantly reduced the level of Ig light chain secretion
(Fig. 1b i&iii), with a consequent increase in the intracellular reten-
tion level (Fig. 1b ii&iv). The net result of this inhibition would be
to increase the intracellular protein load, leading to increased cell
stress and cell death.
Since only correctly folded Ig can be secreted from the cell,
incompletely folded or misfolded Ig is either retained in the cell
for further folding, or targeted for proteasomal degradation [22–
24]. In this respect, Hsp70 isoforms are known to mediate the ubiq-
uitination of their substrate proteins via interaction with their co-
chaperone CHIP, an E3 ubiquitin ligase, thereby targeting them for
proteasomal degradation [20,25]. To study the mechanism of Ig
light chain retention in cells following Hsp70 silencing, we investi-
gated whether Hsp70 isoforms were involved in proteasomal deg-
radation in MM cells. Following Hsc70 but not Hsp72 silencing,
total ubiquitination levels were decreased in both cell lines and
in KMS11 dual silencing reduced ubiquitination levels further
(Fig. 1c i&ii). This result suggests that Hsp70 isoforms are involved
in proteasomal targeting and is consistent with the observed in-
crease in Ig retention following Hsp70 silencing described above.
To determine if the Ig light chains physically interacted with
Hsc70 or Hsp72, we immunoprecipitated IgK or Igk, secreted by
KMS11 and RPMI8226 cells respectively, followed by western blot-
ting and staining for Hsp72 and Hsc70. We show that although
intracellular Ig retention was only observed following Hsc70
silencing, Ig light chains interacted with both Hsp72 and Hsc70
(Fig. 1f), a result which suggests that both Hsp70 isoforms are in-
volved in Ig homeostasis in MM, with Hsc70 playing the key role.
3.2. Dual silencing of Hsp72/Hsc70 enhances MM cell death compared
to Hsc70 silencing alone
In order to determine if the intracellular accumulation of
immunoglobulin and proteotoxic stress resulted in an alteration
in myeloma cell growth and survival, we performed WST-1 assays
on cells knocked down for Hsp72 or Hsc70 to measure the number
of metabolically active cells. The results of these experiments show
that the silencing of Hsc70 signiﬁcantly reduced the number of
cells over time compared to the controls, whilst silencing Hsp72
had no signiﬁcant effect (Fig. 2a i&ii). Following Hsc70 silencing
using two shRNAs (Fig. 2a ii), cell number was reduced by 80% in
both cell lines despite a signiﬁcant upregulation of Hsp72
(Fig. 1a). ShRNA #1 in RPMI8226 cells did not induce a signiﬁcant
cell number change in RPMI8226 cells and this is in line with the
much lower knockdown level achieved with this particular shRNA
(Fig. 1a ii). This decrease in metabolically active cells correlates
with the increased level of Ig retention following Hsc70 silencing
(Fig. 1b). Thus overall, our data suggests that Hsc70 plays an
important role in Ig homeostasis that is critical to MM cell survival
and that its function cannot be compensated for by Hsp72.
We next studied the effect of dual silencing of Hsp72 and Hsc70
on proliferation and apoptosis using WST-1, Annexin V/PI staining
and PI exclusion assays. The results conﬁrm that silencing of Hsc70
but not Hsp72 signiﬁcantly reduced cell numbers over time in
KMS11 and RPMI8226 cells (Fig. 2b i&ii). In addition, combined
knockdown of both Hsp72 and Hsc70 consistently reduced the
survival of MM cells to a greater extent than single isoform silenc-
ing. Annexin V/PI double staining and PI exclusion assays showthat the change in cell numbers is at least in part via apoptosis
in KMS11 cells (Fig. 2c and d) and similar results were obtained
in RPMI8226 cells (data not shown). Ten days after knockdown,
most cells had died with dual silencing (Fig. 2c and d). These re-
sults show that while targeting Hsc70 alone is effective in killing
MM cells, combined inhibition of both Hsp72 and Hsc70 is better.
3.3. Silencing Hsp72 and Hsc70 triggers multiple cellular responses
that contribute to MM cell death
In addition to increasing intracellular Ig, based on their func-
tional roles, we postulated that other mechanisms of Hsp70 may
also be important in MM. To investigate the other potential roles
of Hsp70, we studied the effect of Hsp72 and Hsc70 silencing on
pathways known to be important for MM survival. As previously
noted, knockdown of Hsp72 had no effect on the level of Hsc70,
whereas silencing Hsc70 resulted in a signiﬁcant upregulation of
Hsp72 (Fig. 3a and f). The level of Hsp90 protein did not change fol-
lowing silencing of either Hsp72 or Hsc70 alone, or in combination
(Fig. 3a and f). To understand the complex interactions of Hsp70
isoforms with Hsp90 chaperone activity, we examined the Hsp90
client proteins CDK4 and C-RAF after Hsp70 knockdown. The level
of client proteins remained constant after single Hsp72 knock-
down, whereas following single Hsc70 knockdown, CDK4 was de-
pleted in both KMS11 and RPMI8226 cells and C-RAF was
depleted in RPMI8226 cells. Dual knockdown further depleted
CDK4 in both cell lines and C-RAF in RPMI8226 cells. These results
conﬁrm that both Hsp70 isoforms are actively involved in Hsp90-
dependent chaperoning system, but in MM Hsc70 seems to play a
more important role.
Hsf-1 is the major heat shock transcription factor responsible
for the transcriptional induction of a range of heat shock proteins
during the stress response [26]. Therefore, we studied the effect
of Hsp72 and Hsc70 knockdown on Hsf-1 expression. Interestingly,
Hsf-1 expression was induced following Hsp72 knockdown in
RPMI8226 cells (Fig. 3g) and reduced in both cell lines following
Hsc70 knockdown and dual knockdown (Fig. 3b and g), whereas
in KMS11 cells, following single Hsp72 knockdown, Hsf-1
expression is also reduced (Fig. 3b). To further control this experi-
ment we also tested the cells with heat shock at 42 C for 30 min,
which resulted in induced level of Hsf-1 protein (data not shown).
The biological differences in the two cell lines may account for the
discrepancies observed, but based on these observations we con-
clude that 72/70 knockdown does not induce Hsf-1 at protein level.
In addition to Hsp72 and Hsc70, BIP/GRP78 is a critical ER iso-
form of Hsp70 which plays a role in ER protein folding and target-
ing misfolded proteins for proteasomal degradation as well as
regulating the unfolded protein response (UPR) via IRE1, ATF6
and PERK [27]. We show that the level of BIP expression does not
change following Hsp72 knockdown, whereas following Hsc70
knockdown it is upregulated (Fig. 3c and h). This upregulation of
BIP may act as a compensatory mechanism increasing protein fold-
ing capacity and elevating pro-survival UPR signalling pathways
following Hsp70 knockdown, and could in part explain the differ-
ential effects of Hsc70 and Hsp72 outlined above.
As the Hsp70 isoforms are known to play important anti-apop-
totic roles, we next studied the effect of Hsp72 and Hsc70 knock-
down on Caspase-3 cleavage, the main effector caspase involved
in both the intrinsic and extrinsic apoptotic pathways. We show
that the level of pro-Caspase 3 was reduced and that the level of
cleaved-Caspase 3 increased following Hsc70 but not Hsp72
knockdown, suggesting that Hsc70 knockdown induced cell death,
at least in part, was mediated via caspase dependent apoptosis.
Simultaneous silencing of Hsc70 and Hsp72 further reduced pro-
Caspase 3, consistent with the results of cell apoptosis assays
(Fig. 3d and i).
Fig. 1. Silencing of Hsc70 increased paraprotein load and reduced total ubiquitination. (a) KMS11 and RPMI8226 human MM cells were transduced with shRNAs, empty
vector (EC) or scramble controls (C). Western blot analysis was performed to determine the level of Hsp72 or Hsc70 protein. (b) (i) ELISA analysis of the level of IgK secretion
after lentiviral transduction in KMS11 cells. (ii) ELISA assay of the level of IgK retention in KMS11 cells. (iii) ELISA analysis of Igk secretion in RPMI8226 cells. (iv) ELISA assay
of Igk retention in RPMI8226 cells. Results represent the average readings taken from two shRNAs. Results are representative of three independent experiments, ⁄p < 0.05. (c)
Western blot analysis of the level of ubiquitination in protein samples collected from (i) KMS11 cells and (ii) RPMI8226 cells after lentiviral transduction. (d)
Immunoprecipitation study on protein samples collected after transduction. Cell lysate was immunoprecipitated with (i) IgK in KMS11 and (ii) Igk in RPMI8226 followed by
western blot detection of Hsc70 and Hsp72.
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agy in mammalian cells [28,29], and it is known that autophagy
plays a role in MM cell survival [30–32]. We, therefore, studied
the impact of Hsp72 and Hsc70 knockdown on the level of the
chaperone-mediated autophagy marker LAMP-2A. FollowingHsp72 silencing, LAMP-2A levels were unchanged but following
Hsc70 silencing it was signiﬁcantly increased. Dual silencing of
Hsp72 and Hsc70 further increased the LAMP-2A level (Fig. 3e
and j). We suggest that the induction of LAMP-2A following
Hsp70 knockdown may be a compensatory response to maintain
Fig. 2. Lentiviral shRNA knockdown of Hsp72 and Hsc70 signiﬁcantly reduced cell growth and induced apoptosis. (a) WST-1 assay to assess cell proliferation. (i) KMS11 cells
and (ii) RPMI8226 cells. (b) WST-1 assay to assess cell proliferation following dual knockdown. Results represent the average readings taken from two shRNAs. Graph
represents mean values of triplicate determinations. Error bars represent standard deviation. (c) Annexin V/PI double staining assay. The corresponding % live (AV/PI),
apoptotic (AV+/PI), dead (AV+/PI+) and necrotic (AV/PI+) cells are shown in quadrants. (d) PI exclusion assay. The % cell population with sub G1 staining is shown on graph.
All results shown are representative of three independent experiments.
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survival.
Taken together in these experiments we show that Hsp70s, in
particular Hsc70, are involved in multiple oncogenic pathways
contributing to MM survival and targeting the Hsp70s for therapy
could be useful clinically.
3.4. A small-molecule inhibitor of Hsp70 reduces the viability of MM
cell lines and caused molecular level changes similar to the shRNA
silencing of Hsp70 isoforms
To validate our shRNA ﬁndings, we investigated the impact of
the cell-permeable chemical inhibitor Ver-155008, which is known
to inhibit both Hsp72 and Hsc70 [33], in a panel of MM cell lines.
We showed in a WST-1 assay that all MM cell lines tested were
sensitive to the inhibitor (Fig. 4a), with signiﬁcant inhibition of cell
number changes over time, even at the lowest concentration tested
(10 lM) (Fig. 4b). There was however differential sensitivity, with
U266 cells being more resistant in comparison to KMS11 and
RPMI8226 cells (Fig. 4c). In addition, exposure to Ver-155008 for
24 h resulted in increased reactive oxygen species (ROS) produc-
tion in KMS11 and RPMI8226 cells (Supplementary Fig. 1), consis-
tent with the induction of apoptosis observed by Annexin V/PI
double staining assay.
Treatment with Ver-155008 also resulted in Hsp90 client pro-
tein depletion, Caspase-3 cleavage, LAMP-2 and Ig protein reten-
tion (Fig. 4d). All of these molecular changes are consistent with
those observed following shRNA knockdown. Thus small molecule
inhibition of Hsc70 and Hsp72 is able to recapitulate the effects of
speciﬁc shRNA knockdown especially reducing Hsp90 client onco-
genic protein levels, altering chaperone-mediated autophagy, and
deregulating protein homeostasis resulting in MM cell death.We then went onto study the effect of chemical Hsp70 inhibi-
tion in primary MM and peripheral blood mononuclear cell (PBMC)
cells which were used as a non-myeloma control. The primary
CD138 + MM cells were signiﬁcantly more sensitive to Hsp70 inhi-
bition compared to the PBMC cells (Fig. 4e), providing further evi-
dence that targeting Hsp70 is a good treatment strategy for MM.
Moreover, we observed that the lethal effect of Hsp70 chemical
inhibition on MM cells could not be rescued by co-culturing with
bone marrow stromal cells (BMSC) (data not shown), suggesting
that the bone marrow microenvironment cannot protect MM cells
from hsp70 inhibition induced cell death. In addition, We also
show that the combination treatment with Ver-155008 and 17-
AAG for 24 h induced either additive or synergistic antiprolifera-
tive effects in KMS11 and RPMI8226 cells (Supplementary Fig. 2),
supporting the use of hsp70/hsp90 double inhibition as an effective
therapeutic strategy in MM.4. Discussion
Myeloma remains an incurable malignancy and more effective
biologically-based therapeutic strategies are required. In this
study, we investigated the role of therapeutically targeting the
main cytoplasmic Hsp70 isoforms. We hypothesized that myeloma
cells are differentially sensitive compared to other cells within the
body to proteotoxic stress because of their role in immunoglobulin
synthesis. Further, their survival is supported by both the heat
shock pathway and UPR because these molecular processes are
essential for Ig folding and efﬁcient protein degradation via the
proteosome and autophagy, which both regulate intracellular pro-
teotoxic stress maintaining cellular survival.
Fig. 2 (continued)
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effective in in vitro and in vivo models, but so far has been dis-
appointing in clinical myeloma studies [11,20], possibly because
of Hsp70 induction [34]. The Hsp70 isoforms have a range of
functions including protein folding, protection from apoptosis
and the control of protein degradation pathways. Hsp70s act
as co-chaperones of the Hsp90 chaperone complex by present-
ing client proteins to Hsp90; recruiting E3 ubiquitin ligases
such as CHIP to tag target proteins for proteasomal degradation
[35]; participating in chaperone-mediated autophagy and inhib-iting both the caspase-dependent and -independent apoptosis
pathways at multiple levels [36]. All of these observations sug-
gest that Hsp70 targeting would be an effective therapeutic
strategy for myeloma.
In this study, we conﬁrm and extend previous works showing
the importance of Hsp70 family members in myeloma and other
cancers [34,37]. Here, we show that silencing of Hsc70 alone signif-
icantly reduces the proliferation and increases apoptosis of MM
cells. In contrast, silencing of Hsp72 alone did not have an impact
on cell survival, whereas simultaneous silencing of both Hsp70 iso-
Fig. 3. Silencing of Hsp72 and Hsc70 depleted Hsp90 client proteins, enhanced Caspase 3 cleavage and induced protein stress pathways. Western blot analysis was performed
on lentivirally transduced KMS11 and RPMI8226 cells with Hsp72 and/or Hsc70. Beta-actin was used as a loading control.
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both Hsp70 isoforms have a role in MM cell survival. The inducible
Hsp72 and constitutively active Hsc70 isoforms share 85% se-
quence homology, and are thought to have some compensatory
roles [34]. However, the signiﬁcant induction of Hsp72 protein fol-
lowing Hsc70 knockdown could not rescue the cell death pheno-
type, suggesting that Hsc70 may have speciﬁc functions in MM
that cannot be recapitulated by Hsp72. The pro-survival impor-
tance of Hsp72 and Hsc70 has been shown to vary between differ-
ent cancer types. For example, only simultaneous knockdown of
both Hsp72 and Hsc70 was able to induce cell death in solid tu-
mour cell lines [34], yet in the case of MM cell lines we were able
to induce cell death by a single knockdown of Hsc70, consistent
with Hsc70 playing a potentially more important role in MM
survival.
One of the most interesting ﬁndings of this study is the accumu-
lation of immunoglobulin in MM cells following Hsc70 silencing,
which increased proteotoxic stress and cell death. The reduction
in Ig secretion that mirrors intracellular retention suggests that
the immunoglobulin increase following shRNA knockdown is
caused by increased cellular accumulation instead of increased
protein production. Since unfolded Ig is degraded via the ubiquitin
proteasome pathway [38,39], we investigated the effect of Hsp70
knockdown on ubiquitination level. We show that Hsc70 knock-down reduced total ubiquitinated protein levels that were further
reduced by dual Hsc70/Hsp72 knockdown. Since only correctly
folded Ig can be secreted from cells, our observations suggest that
the accumulation of Ig which follows Hsp70 knockdown is also
accompanied by reduced clearance via proteasomal degradation.
The net result of reduced secretion and increased cellular retention
is to signiﬁcantly increase the proteotoxic stress in MM cells,
which triggers apoptosis. We also show that both Hsc70 and
Hsp72 interact directly with Ig, suggesting that the Hsp70s have
a role in regulating Ig stability and the two isoforms may play com-
pensatory roles. However, since only Hsc70 silencing resulted in Ig
accumulation, our results provide further evidence that the Hsc70
has an irreplaceable role in MM.
In addition to the effects on immunoglobulin, silencing of
Hsp70 isoform functions also resulted in a number of other effects
that may speciﬁcally promote MM cell death. Chaperone-mediated
autophagy is a type of lysosomal degradation responsible for the
clearance of a range of soluble cytosolic proteins bearing the
KFERQ-related motif, which can be recognised by the Hsp70 chap-
erone complex [28,40]. Hsp70 delivers its target protein to the
lysosome surface and presents it to the chaperone-mediated
autophagy receptor LAMP-2A [41]. At this site, Hsp70 assists the
unfolding of the substrate protein, enabling its translocation into
the lysosomal lumen [29]. Autophagocytosis plays an important
Fig. 4. Small-molecule Hsp70 inhibitor strongly induced apoptosis and inhibited cell growth of MM cell lines. (a) EC50 curves of a panel of MM cell lines treated with Ver-
155008 for 24 h as determined byWST-1 assay. (b) Dose- and time-dependent response of four humanMM cell lines treated with Ver-155008. (c) Annexin V/PI staining assay
for cell survival following 24-h treatment of four MM cell lines using Ver-155008. (a–c) Graphs represent mean values taken from triplicate determinations, error bars
represents standard deviation. (d) Western blot analysis on KMS11 and RPMI8226 cells treated with 15 Ver-155008 for 24 h. (e) Dose dependent response of primary MM and
normal peripheral blood mononuclear cells treated with Ver-155008 for 24 h as determined by WST-1 assay. Graph represents mean values taken from all cell samples with
duplicate readings. Error bars represents standard deviation.
56 L. Zhang et al. / Cancer Letters 339 (2013) 49–59role in protein homeostasis and recent evidence suggests that
macroautophagy regulates MM cell survival [30–32]. How chaper-
one-mediated autophagy contributes to MM survival is still un-
clear. The increase in LAMP-2A expression following Hsp70
knockdown suggests a compensatory mechanism to maintainchaperone-mediated autophagy for survival, since substrate load-
ing to LAMP-2A is the rate-limiting step [42,43].
We also studied the roles of Hsp70 as a co-chaperone of Hsp90
in MM. Hsp90 is required in the activation and maturation of a
range of client proteins, many of which are key transcription fac-
Fig. 4 (continued)
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[44]. It has been previously shown in solid tumour cells that
Hsc70 acts as the primary co-chaperone for Hsp90; Hsp72, on
the other hand, can compensate for the loss of Hsc70 and replace
it in the Hsp90 chaperone complex [34]. We studied two client
proteins of Hsp90, known to be involved in cell cycle control
(CDK4) and proliferative signal transduction (C-RAF). Interestingly,
Hsc70 silencing alone resulted in CDK4 depletion in MM cells and
dual Hsc70/Hsp72 silencing induced further depletion, whereas C-RAF was only depleted in RPMI8226 cells following Hsc70 silenc-
ing. These results conﬁrm the involvement of both Hsp70 isoforms
in Hsp90 client protein maturation/degradation, contributing to
MM cell survival. The varying responses of the different client
proteins to Hsp70 isoform silencing suggests that Hsp90 client pro-
teins may be differentially dependent on Hsp70 isoforms as co-
chaperones. Hsc70 may act as the main co-chaperone for CDK4
in both cell lines. C-RAF, on the other hand, appears not to be
dependent on these Hsp72 isoforms in KMS11 cells.
Fig. 5. Proposed mechanisms of Hsp70s contributing to MM cell survival. Our results demonstrate that the Hsp70 isoforms Hsc70 and Hsp72 play a variety of roles within the
MM cell particularly with respect to protein homeostasis and the regulation of proteotoxic stress.
58 L. Zhang et al. / Cancer Letters 339 (2013) 49–59Both Hsp72 and Hsc70 have been known to directly interact
with Hsf-1 [45,46], the master regulator of the heat shock re-
sponse, responsible for the upregulation of a subset of inducible
heat shock proteins [47]. Hsp72 negatively regulates Hsf-1 tran-
scriptional activity, whereas Hsc70 is required for the activation
of Hsf-1 [45,46]. We observed an upregulation of Hsf-1 following
Hsp72 knockdown in RPMI8226 cells, which may be the heat shock
response of RPMI8226 cells trying to re-balance heat shock protein
levels following the loss of Hsp72. The downregulation of Hsf-1 we
observed following Hsp70 knockdown and dual knockdown in
both KMS11 and RPMI8226 cells suggests a negative feedback loop
in the heat shock response, which may be a late-stage event after
the induction of Hsp72. The downregulation of Hsf-1 following
Hsp72 knockdown in KMS11 cells by an unknown mechanism is
in contrast to RPMI8226 cells, and may reﬂect the biological differ-
ence between the myeloma cell lines. Overall, the downregulation
of Hsf-1 may contribute to MM cell death following Hsp70 silenc-
ing, by weakening the ability of MM cells to cope with proteotoxic
stress.
The observation of consistent biological outcomes following
small-molecule inhibition or shRNA knockdown provides conﬁ-
dence in the biological effect of Hsp70 inhibition, and points to
the involvement of particular functional mechanisms rather than
scaffolding effects [48]. By using a chemical inhibitor acting on
both Hsp72 and Hsc70 to block ATP binding and hydrolysis [33],
we were able to validate and extend our shRNA data. We show that
in a panel of MM cell lines the Hsp70 inhibitor was able to induce
MM cell apoptosis with or without the protection of the bone mar-
row microenvironment, with associated changes in Hsp90 client
proteins and chaperone-mediated autophagy. Moreover, we
showed that primary MM cells were also killed in response to
the Hsp70 inhibitor and that they are signiﬁcantly more sensitive
compared to normal peripheral blood mononuclear cells. These re-
sults suggest that there is a potential therapeutic window that
could be exploited in the clinic [34].
We have previously shown that the inhibition of Hsp72 en-
hances Hsp90 inhibitor-induced apoptosis in myeloma cells, con-
ﬁrming the potential of targeting Hsp70s in myeloma in
combination with Hsp90 [49]. In this study, we were able to pro-
vide additional data supporting the use of Hsp70 inhibition in mye-
loma treatment, either alone or in combination with Hsp90inhibition. We have also extended our work to show the different
roles that Hsp72 and Hsc70 play in myeloma cells, and their
involvement in the various molecular pathways known to be
important to myeloma survival. We propose that the mechanism
of effective cell killing observed following Hsp70 inhibition is the
collective result of targeting multiple pathways, leading to the
alteration in protein homeostasis - the key to myeloma cell sur-
vival (summarised in Fig. 5). The development of an effective
Hsp70 inhibitor suitable for clinical use is, therefore, eagerly
awaited.Funding
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